TSE:AEZS Aeterna Zentaris (AEZS) Stock Price, News & Analysis C$5.10 0.00 (0.00%) (As of 10/11/2024) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlines About Aeterna Zentaris Stock (TSE:AEZS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aeterna Zentaris alerts:Sign Up Key Stats Today's RangeC$5.10▼C$5.1050-Day RangeC$4.84▼C$8.3352-Week RangeC$5.40▼C$16.08Volume286 shsAverage Volume1,137 shsMarket CapitalizationC$15.61 millionP/E RatioN/ADividend Yield2.79%Price TargetN/AConsensus RatingN/A Company OverviewAeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.Read More… True paradigm shift (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Receive AEZS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter. Email Address AEZS Stock News HeadlinesClosing Bell: Aeterna Zentaris Inc up on Monday (AEZS)July 30, 2024 | theglobeandmail.comAEZS:CA Aeterna Zentaris Inc.July 29, 2024 | seekingalpha.comCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!November 2, 2024 | Crypto 101 Media (Ad)Closing Bell: Aeterna Zentaris Inc flat on Friday (AEZS)July 20, 2024 | theglobeandmail.comCeapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna MergerMay 29, 2024 | finance.yahoo.comCancer Cachexia Pipeline Insights Report, 2024 Featuring Emerging Drugs Macimorelin (AEterna Zentaris) and PF-06946860 (Pfizer)May 22, 2024 | finance.yahoo.comAeterna Zentaris Finalizes Some Details for Ceapro MergerMay 17, 2024 | finance.yahoo.comAEterna Zentaris: Top 10 Undervalued Healthcare Sector Stocks on TSX (AEZS)May 1, 2024 | theglobeandmail.comSee More Headlines AEZS Stock Analysis - Frequently Asked Questions How have AEZS shares performed this year? Aeterna Zentaris' stock was trading at C$2.57 at the beginning of the year. Since then, AEZS shares have increased by 98.4% and is now trading at C$5.10. View the best growth stocks for 2024 here. How do I buy shares of Aeterna Zentaris? Shares of AEZS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Aeterna Zentaris own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aeterna Zentaris investors own include Meta Platforms (META), Novavax (NVAX), Verizon Communications (VZ), Western Uranium & Vanadium (WUC), Air Canada (AC), Affirm (AFRM) and AutoZone (AZO). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolTSE:AEZS CUSIPN/A CIKN/A Webwww.aezsinc.com Phone18439003223FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($3.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-18,050,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.71% Return on Assets-29.96% Debt Debt-to-Equity Ratio1.80 Current Ratio5.94 Quick Ratio9.37 Sales & Book Value Annual SalesC$2.37 million Price / Sales6.58 Cash FlowC$11.13 per share Price / Cash Flow0.46 Book ValueC$10.68 per share Price / Book0.48Miscellaneous Outstanding Shares3,060,000Free FloatN/AMarket CapC$15.61 million OptionableNot Optionable Beta2.26 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (TSE:AEZS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aeterna Zentaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.